Eating Disorders Genetics Initiative 2
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · Sep 10, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Eating Disorders Genetics Initiative 2 (EDGI2) is a research study aimed at understanding eating disorders like anorexia nervosa, bulimia nervosa, binge-eating disorder, and avoidant/restrictive food intake disorder. The goal is to enroll 20,000 participants from various backgrounds to gather a wide range of information. Researchers want to learn more about how these disorders are connected and how they can develop better treatments. Participants will be asked to fill out some questionnaires and provide a saliva sample, which will help scientists study the genetics of eating disorders.
To be eligible for this study, you need to be between the ages of 12 and 99 (with U.S. participants aged 18-99) and have a history of one of the eating disorders mentioned or no history of disordered eating. The study is looking for a diverse group of participants, especially from underrepresented communities. If you choose to take part, your contributions could help improve the understanding of eating disorders and support the development of more effective treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A lifetime history of anorexia nervosa, bulimia nervosa, binge-eating disorder, avoidant restrictive food intake disorders or no history of any disordered eating behavior, based on DSM-5 criteria algorithms
- • Age 12-99 years, depending on country. (US enrollment age is 18-99)
- Exclusion Criteria:
- • History of subthreshold disordered eating behaviors.
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Brisbane, Queensland, Australia
Christchurch, Canterbury, New Zealand
Chapel Hill, North Carolina, United States
Monterrey, , Mexico
Patients applied
Trial Officials
Cynthia Bulik, PhD
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported